

12 December 2007



**National Institute for
Health and Clinical Excellence**

MidCity Place

71 High Holborn

London

WC1V 6NA

Tel: +44 (0)20 7067 5800

Fax: +44 (0)20 7067 5801

nice@nice.org.uk

www.nice.org.uk

**Crohn's disease - infliximab (review), certolizumab pegol and
adalimumab
REMOVAL of certolizumab pegol**

Dear Consultees and Commentators,

I am writing to formally confirm that following marketing authorisation delays, certolizumab pegol has been removed from the Crohn's disease appraisal. The next communication you can expect for this appraisal is the Assessment Report, which will go out for consultation in late January 2008.

Yours Sincerely

Dr Carole Longson
Programme Director
National Institute for Clinical Excellence